{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:58:28Z","timestamp":1791316708727,"version":"4.3.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"24","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260546"],"award-info":[{"award-number":["82260546"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473364"],"award-info":[{"award-number":["82473364"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,7,1]]},"DOI":"10.1038\/s41388-026-03798-6","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T05:41:16Z","timestamp":1777441276000},"page":"2342-2358","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["KDM4B\/DHX9 promotes chemoresistance in small-cell lung cancer through the MYCN-driven signaling pathway"],"prefix":"10.1038","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3298-7674","authenticated-orcid":false,"given":"Qiong","family":"Lyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9947-418X","authenticated-orcid":false,"given":"Weitao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxuan","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianshan","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8488-9535","authenticated-orcid":false,"given":"Xiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7217-0111","authenticated-orcid":false,"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8028-5621","authenticated-orcid":false,"given":"Jian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"3798_CR1","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/s41571-024-00914-x","volume":"21","author":"T Sen","year":"2024","unstructured":"Sen T, Takahashi N, Chakraborty S, Takebe N, Nassar AH, Karim NA, et al. Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer. Nat Rev Clin Oncol. 2024;21:610\u201327.","journal-title":"Nat Rev Clin Oncol"},{"key":"3798_CR2","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.trecan.2024.07.008","volume":"10","author":"E Redin","year":"2024","unstructured":"Redin E, Quintanal-Villalonga \u00c1, Rudin CM. Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity. Trends Cancer. 2024;10:935\u201346.","journal-title":"Trends Cancer"},{"key":"3798_CR3","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/JCO.1992.10.2.282","volume":"10","author":"BJ Roth","year":"1992","unstructured":"Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992;10:282\u201391.","journal-title":"J Clin Oncol"},{"key":"3798_CR4","doi-asserted-by":"publisher","unstructured":"Stein S, Roy MB, Stein K, Aaseb\u00f8 U, Hatlevoll R, Dahle R, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years\u2019 follow-up. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20. https:\/\/doi.org\/10.1200\/JCO.2002.12.111.","DOI":"10.1200\/JCO.2002.12.111"},{"key":"3798_CR5","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220\u20139.","journal-title":"N Engl J Med"},{"key":"3798_CR6","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929\u201339.","journal-title":"Lancet"},{"key":"3798_CR7","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"M-J Ahn","year":"2023","unstructured":"Ahn M-J, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389:2063\u201375.","journal-title":"N Engl J Med"},{"key":"3798_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189253","volume":"1880","author":"A Verma","year":"2025","unstructured":"Verma A, Khan MA, Satrusal SR, Datta D. Emerging role of EZH2 in solid tumor metastasis. Biochim Biophys Acta Rev Cancer. 2025;1880:189253.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3798_CR9","doi-asserted-by":"publisher","unstructured":"Irene F, Michele DL, Elena J. Exploring the role of EZH2 modulation in shaping the tumor microenvironment. Epigenomics. 2024;16. https:\/\/doi.org\/10.1080\/17501911.2024.2410693.","DOI":"10.1080\/17501911.2024.2410693"},{"key":"3798_CR10","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ccell.2017.01.006","volume":"31","author":"EE Gardner","year":"2017","unstructured":"Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, et al. Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis. Cancer Cell. 2017;31:286\u201399.","journal-title":"Cancer Cell"},{"key":"3798_CR11","doi-asserted-by":"publisher","first-page":"4717","DOI":"10.7150\/thno.33680","volume":"9","author":"Z Qiu","year":"2019","unstructured":"Qiu Z, Zhu W, Meng H, Tong L, Li X, Luo P, et al. CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter. Theranostics. 2019;9:4717\u201329.","journal-title":"Theranostics"},{"key":"3798_CR12","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.3390\/biology13121008","volume":"13","author":"L Reed","year":"2024","unstructured":"Reed L, Abraham J, Patel S, Dhar SS. Epigenetic modifiers: exploring the roles of histone methyltransferases and demethylases in cancer and neurodegeneration. Biology. 2024;13:1008.","journal-title":"Biology"},{"key":"3798_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aau2922","volume":"12","author":"A Augert","year":"2019","unstructured":"Augert A, Eastwood E, Ibrahim AH, Wu N, Grunblatt E, Basom R, et al. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition. Sci Signal. 2019;12:eaau2922.","journal-title":"Sci Signal"},{"key":"3798_CR14","doi-asserted-by":"publisher","unstructured":"Bauer TM, Besse B, Martinez-Marti A, Trigo JM, Moreno V, Garrido P, et al. Phase I, Open-Label, dose-escalation study of the safety, pharmacokinetics, pharmacodynamics, and efficacy of GSK2879552 in relapsed\/refractory SCLC. J Thorac Oncol. 2019; 14. https:\/\/doi.org\/10.1016\/j.jtho.2019.06.021.","DOI":"10.1016\/j.jtho.2019.06.021"},{"key":"3798_CR15","doi-asserted-by":"crossref","unstructured":"Wilson C, Krieg AJ. KDM4B: a nail for every hammer? Genes. 2019;10:134.","DOI":"10.3390\/genes10020134"},{"key":"3798_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/cas.16005","volume":"115","author":"F Ni","year":"2024","unstructured":"Ni F, Tang H, Cheng S, Yu Y, Yuan Z, Chen Y, et al. KDM4B: a promising oncology therapeutic target. Cancer Sci. 2024;115:8\u201316.","journal-title":"Cancer Sci"},{"key":"3798_CR17","doi-asserted-by":"publisher","unstructured":"Liu Z, Suh J, Deng P, Bezouglaia O, Do M, Mirnia M, et al. Epigenetic regulation of NGF-mediated osteogenic differentiation in human dental mesenchymal stem cells. Stem cells. 2022; 40. https:\/\/doi.org\/10.1093\/stmcls\/sxac042.","DOI":"10.1093\/stmcls\/sxac042"},{"key":"3798_CR18","doi-asserted-by":"publisher","first-page":"E5566","DOI":"10.1073\/pnas.1721814115","volume":"115","author":"Y Cheng","year":"2018","unstructured":"Cheng Y, Yuan Q, Vergnes L, Rong X, Youn JY, Li J, et al. KDM4B protects against obesity and metabolic dysfunction. Proc Natl Acad Sci USA. 2018;115:E5566\u201375.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3798_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-79601-7","volume":"11","author":"KH-M Mak","year":"2021","unstructured":"Mak KH-M, Lam YM, Ng RK. Histone demethylase JMJD2B\/KDM4B regulates transcriptional program via distinctive epigenetic targets and protein interactors for the maintenance of trophoblast stem cells. Sci Rep. 2021;11:884.","journal-title":"Sci Rep"},{"key":"3798_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.790129","volume":"9","author":"Z Wang","year":"2021","unstructured":"Wang Z, Cai H, Zhao E, Cui H. The diverse roles of histone demethylase KDM4B in normal and cancer development and progression. Front Cell Dev Biol. 2021;9:790129.","journal-title":"Front Cell Dev Biol"},{"key":"3798_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1305-y","volume":"10","author":"M-C Wu","year":"2019","unstructured":"Wu M-C, Cheng H-H, Yeh T-S, Li Y-C, Chen T-J, Sit WY, et al. KDM4B is a coactivator of c-Jun and involved in gastric carcinogenesis. Cell Death Dis. 2019;10:68.","journal-title":"Cell Death Dis"},{"key":"3798_CR22","doi-asserted-by":"publisher","DOI":"10.1080\/15592294.2023.2192319","volume":"18","author":"H Tang","year":"2023","unstructured":"Tang H, Guan Y, Yuan Z, Guo T, Tan X, Fan Y, et al. Histone demethylase KDM4B contributes to advanced clear cell renal carcinoma and association with copy number variations and cell cycle progression. Epigenetics. 2023;18:2192319.","journal-title":"Epigenetics"},{"key":"3798_CR23","doi-asserted-by":"publisher","first-page":"5763","DOI":"10.7150\/thno.38087","volume":"10","author":"J Tan","year":"2020","unstructured":"Tan J, Wang H-L, Yang J, Liu Q-Q, Li C-M, Wang Y-Q, et al. JMJD2B-induced amino acid alterations enhance the survival of colorectal cancer cells under glucose-deprivation via autophagy. Theranostics. 2020;10:5763\u201377.","journal-title":"Theranostics"},{"key":"3798_CR24","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/s41591-019-0638-5","volume":"25","author":"JA Seoane","year":"2019","unstructured":"Seoane JA, Kirkland JG, Caswell-Jin JL, Crabtree GR, Curtis C. Chromatin regulators mediate anthracycline sensitivity in breast cancer. Nat Med. 2019;25:1721\u20137.","journal-title":"Nat Med"},{"key":"3798_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.114077","volume":"158","author":"L Duan","year":"2023","unstructured":"Duan L, Chen Y-A, Liang Y, Chen Z, Lu J, Fang Y, et al. Therapeutic targeting of histone lysine demethylase KDM4B blocks the growth of castration-resistant prostate cancer. Biomed Pharmacother. 2023;158:114077.","journal-title":"Biomed Pharmacother"},{"key":"3798_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/path.5495","volume":"252","author":"D-E Tang","year":"2020","unstructured":"Tang D-E, Dai Y, He J-X, Lin L-W, Leng Q-X, Geng X-Y, et al. Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen receptor-targeted therapy in advanced prostate cancer. J Pathol. 2020;252:101\u201313.","journal-title":"J Pathol"},{"key":"3798_CR27","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1084\/jem.20180439","volume":"215","author":"W Wang","year":"2018","unstructured":"Wang W, Oguz G, Lee PL, Bao Y, Wang P, Terp MG, et al. KDM4B-regulated unfolded protein response as a therapeutic vulnerability in PTEN-deficient breast cancer. J Exp Med. 2018;215:2833\u201349.","journal-title":"J Exp Med"},{"key":"3798_CR28","doi-asserted-by":"publisher","first-page":"9451","DOI":"10.1021\/ja201597b","volume":"133","author":"X Luo","year":"2011","unstructured":"Luo X, Liu Y, Kubicek S, Myllyharju J, Tumber A, Ng S, et al. A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases. J Am Chem Soc. 2011;133:9451\u20136.","journal-title":"J Am Chem Soc"},{"key":"3798_CR29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2205691119","volume":"119","author":"S Rahman","year":"2022","unstructured":"Rahman S, Hoffmann NA, Worden EJ, Smith ML, Namitz KEW, Knutson BA, et al. Multistate structures of the MLL1-WRAD complex bound to H2B-ubiquitinated nucleosome. Proc Natl Acad Sci USA. 2022;119:e2205691119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3798_CR30","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nature16952","volume":"530","author":"Y Li","year":"2016","unstructured":"Li Y, Han J, Zhang Y, Cao F, Liu Z, Li S, et al. Structural basis for activity regulation of MLL family methyltransferases. Nature. 2016;530:447\u201352.","journal-title":"Nature"},{"key":"3798_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/13543776.2024.2441658","volume":"35","author":"JA Coker","year":"2025","unstructured":"Coker JA, Stauffer SR. WD repeat domain 5 (WDR5) inhibitors: a patent review (2016-present). Expert Opin Ther Pat. 2025;35:31\u201345.","journal-title":"Expert Opin Ther Pat"},{"key":"3798_CR32","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41:D955\u201361.","journal-title":"Nucleic Acids Res"},{"key":"3798_CR33","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","volume":"19","author":"CM Rudin","year":"2019","unstructured":"Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019;19:289\u201397.","journal-title":"Nat Rev Cancer"},{"key":"3798_CR34","doi-asserted-by":"publisher","unstructured":"Shen W, Lyu Q, Yi R, Sun Y, Zhang W, Wei T, et al. HMGB1 promotes chemoresistance in small cell lung cancer by inducing PARP1-related nucleophagy. J Adv Res. 2024; 66. https:\/\/doi.org\/10.1016\/j.jare.2023.12.020.","DOI":"10.1016\/j.jare.2023.12.020"},{"key":"3798_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41413-021-00145-1","volume":"9","author":"S-J Yi","year":"2021","unstructured":"Yi S-J, Jang Y-J, Kim H-J, Lee K, Lee H, Kim Y, et al. The KDM4B-CCAR1-MED1 axis is a critical regulator of osteoclast differentiation and bone homeostasis. Bone Res. 2021;9:27.","journal-title":"Bone Res"},{"key":"3798_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-023-01608-4","volume":"15","author":"Z Wang","year":"2023","unstructured":"Wang Z, Cai H, Li Z, Sun W, Zhao E, Cui H. Histone demethylase KDM4B accelerates the progression of glioblastoma via the epigenetic regulation of MYC stability. Clin Epigenetics. 2023;15:192.","journal-title":"Clin Epigenetics"},{"key":"3798_CR37","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s42003-021-01842-7","volume":"4","author":"L Cai","year":"2021","unstructured":"Cai L, Liu H, Huang F, Fujimoto J, Girard L, Chen J, et al. Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer. Commun Biol. 2021;4:314.","journal-title":"Commun Biol"},{"key":"3798_CR38","doi-asserted-by":"publisher","first-page":"e1005895","DOI":"10.1371\/journal.pgen.1005895","volume":"12","author":"L Jiang","year":"2016","unstructured":"Jiang L, Huang J, Higgs BW, Hu Z, Xiao Z, Yao X, et al. Genomic landscape survey identifies SRSF1 as a key oncodriver in small cell lung cancer. PLoS Genet. 2016;12:e1005895.","journal-title":"PLoS Genet"},{"key":"3798_CR39","doi-asserted-by":"publisher","first-page":"186ra66","DOI":"10.1126\/scitranslmed.3005723","volume":"5","author":"S Rousseaux","year":"2013","unstructured":"Rousseaux S, Debernardi A, Jacquiau B, Vitte A-L, Vesin A, Nagy-Mignotte H, et al. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med. 2013;5:186ra66.","journal-title":"Sci Transl Med"},{"key":"3798_CR40","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cell.2023.12.004","volume":"187","author":"Q Liu","year":"2024","unstructured":"Liu Q, Zhang J, Guo C, Wang M, Wang C, Yan Y, et al. Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies. Cell. 2024;187:184\u2013203.e28.","journal-title":"Cell"},{"key":"3798_CR41","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.jtho.2020.09.009","volume":"15","author":"MK Baine","year":"2020","unstructured":"Baine MK, Hsieh M-S, Lai WV, Egger JV, Jungbluth AA, Daneshbod Y, et al. SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization. J Thorac Oncol. 2020;15:1823\u201335.","journal-title":"J Thorac Oncol"},{"key":"3798_CR42","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ccell.2016.12.005","volume":"31","author":"G Mollaoglu","year":"2017","unstructured":"Mollaoglu G, Guthrie MR, B\u00f6hm S, Br\u00e4gelmann J, Can I, Ballieu PM, et al. MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to aurora kinase inhibition. Cancer Cell. 2017;31:270\u201385.","journal-title":"Cancer Cell"},{"key":"3798_CR43","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1101\/gad.340133.120","volume":"34","author":"E Grunblatt","year":"2020","unstructured":"Grunblatt E, Wu N, Zhang H, Liu X, Norton JP, Ohol Y, et al. MYCN drives chemoresistance in small-cell lung cancer, while USP7 inhibition can restore chemosensitivity. Genes Dev. 2020;34:1210\u201326.","journal-title":"Genes Dev"},{"key":"3798_CR44","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1158\/2159-8290.CD-23-0656","volume":"14","author":"S Pal Choudhuri","year":"2024","unstructured":"Pal Choudhuri S, Girard L, Lim JYS, Wise JF, Freitas B, Yang D, et al. Acquired cross-resistance in small cell lung cancer due to extrachromosomal DNA amplification of MYC paralogs. Cancer Discov. 2024;14:804\u201327.","journal-title":"Cancer Discov"},{"key":"3798_CR45","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adq7084","volume":"11","author":"L Brumage","year":"2025","unstructured":"Brumage L, Best S, Hippe DS, Grunblatt E, Chanana P, Wu F, et al. In vivo functional screens reveal KEAP1 loss as a driver of chemoresistance in small cell lung cancer. Sci Adv. 2025;11:eadq7084.","journal-title":"Sci Adv"},{"key":"3798_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101468","volume":"5","author":"A Abu-Zaid","year":"2024","unstructured":"Abu-Zaid A, Fang J, Jin H, Singh S, Pichavaram P, Wu Q, et al. Histone lysine demethylase 4 family proteins maintain the transcriptional program and adrenergic cellular state of MYCN-amplified neuroblastoma. Cell Rep Med. 2024;5:101468.","journal-title":"Cell Rep Med"},{"key":"3798_CR47","doi-asserted-by":"crossref","unstructured":"Mak CSL, Zhu M, Fu J, Liang X, Wang X, Yuan F, et al. KDM4A promotes NEPC progression through regulation of MYC expression. Cancer Lett. 2025;638:218184.","DOI":"10.1016\/j.canlet.2025.218184"},{"key":"3798_CR48","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1038\/s41388-024-03125-x","volume":"43","author":"A Nguyen","year":"2024","unstructured":"Nguyen A, Nu\u00f1ez CG, Tran TA, Girard L, Peyton M, Catalan R, et al. Jumonji histone demethylases are therapeutic targets in small-cell lung cancer. Oncogene. 2024;43:2885\u201399.","journal-title":"Oncogene"},{"key":"3798_CR49","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nature01493","volume":"422","author":"DN Watkins","year":"2003","unstructured":"Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, Baylin SB. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature. 2003;422:313\u20137.","journal-title":"Nature"},{"key":"3798_CR50","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/nm.2473","volume":"17","author":"K-S Park","year":"2011","unstructured":"Park K-S, Martelotto LG, Peifer M, Sos ML, Karnezis AN, Mahjoub MR, et al. A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat Med. 2011;17:1504\u20138.","journal-title":"Nat Med"},{"key":"3798_CR51","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1002\/cncr.30062","volume":"122","author":"CP Belani","year":"2016","unstructured":"Belani CP, Dahlberg SE, Rudin CM, Fleisher M, Chen HX, Takebe N, et al. Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1508). Cancer. 2016;122:2371\u20138. https:\/\/doi.org\/10.1002\/cncr.30062.","journal-title":"Cancer"},{"key":"3798_CR52","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1158\/0008-5472.CAN-22-2496","volume":"83","author":"LH Cheng","year":"2023","unstructured":"Cheng LH, Hsu CC, Tsai HW, Liao WY, Yang PM, Liao TY, et al. ASPM activates Hedgehog and Wnt signaling to promote small cell lung cancer stemness and progression. Cancer Res. 2023;83:830\u201344. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-2496.","journal-title":"Cancer Res"},{"key":"3798_CR53","unstructured":"Tong Q, Ouyang S, Chen R, JH, LG. MYCN-mediated regulation of the HES1 promoter enhances the chemoresistance of small-cell lung cancer by modulating apoptosis. Am J Cancer Res. 2019; 9.https:\/\/pubmed.ncbi.nlm.nih.gov\/31598396\/."},{"key":"3798_CR54","doi-asserted-by":"publisher","first-page":"a014308","DOI":"10.1101\/cshperspect.a014308","volume":"3","author":"MF Roussel","year":"2013","unstructured":"Roussel MF, Robinson GW. Role of MYC in Medulloblastoma. Cold Spring Harb Perspect Med. 2013;3:a014308.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"3798_CR55","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.stem.2019.10.005","volume":"25","author":"M \u010can\u010der","year":"2019","unstructured":"\u010can\u010der M, Hutter S, Holmberg KO, Ros\u00e9n G, Sundstr\u00f6m A, Tailor J, et al. Humanized stem cell models of pediatric medulloblastoma reveal an Oct4\/mTOR axis that promotes malignancy. Cell Stem Cell. 2019;25:855\u201370.e11.","journal-title":"Cell Stem Cell"},{"key":"3798_CR56","doi-asserted-by":"publisher","first-page":"4206","DOI":"10.1093\/nar\/gkl460","volume":"34","author":"FV Fuller-Pace","year":"2006","unstructured":"Fuller-Pace FV. DExD\/H box RNA helicases: multifunctional proteins with important roles in transcriptional regulation. Nucleic Acids Res. 2006;34:4206\u201315.","journal-title":"Nucleic Acids Res"},{"key":"3798_CR57","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1158\/0008-5472.CAN-24-0397","volume":"85","author":"J Castro","year":"2025","unstructured":"Castro J, Daniels MH, Brennan D, Johnston B, Gotur D, Lee Y-T, et al. A potent, selective, small-molecule inhibitor of DHx9 abrogates proliferation of microsatellite instable cancers with deficient mismatch repair. Cancer Res. 2025;85:758\u201376.","journal-title":"Cancer Res"},{"key":"3798_CR58","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/s41418-023-01160-x","volume":"30","author":"K Yang","year":"2023","unstructured":"Yang K, Zhang W, Zhong L, Xiao Y, Sahoo S, Fassan M, et al. Long non-coding RNA HIF1A-As2 and MYC form a double-positive feedback loop to promote cell proliferation and metastasis in KRAS-driven non-small cell lung cancer. Cell Death Differ. 2023;30:1533\u201349.","journal-title":"Cell Death Differ"},{"key":"3798_CR59","doi-asserted-by":"crossref","unstructured":"Ren X, Wang D, Zhang G, Zhou T, Wei Z, Yang Y, et al. Nucleic DHX9 cooperates with STAT1 to transcribe interferon-stimulated genes. Sci Adv. 2023; 9: eadd5005.","DOI":"10.1126\/sciadv.add5005"},{"key":"3798_CR60","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1158\/2159-8290.CD-23-0486","volume":"14","author":"T Murayama","year":"2024","unstructured":"Murayama T, Nakayama J, Jiang X, Miyata K, Morris AD, Cai KQ, et al. Targeting DHX9 triggers tumor-intrinsic interferon response and replication stress in small cell lung cancer. Cancer Discov. 2024;14:468\u201391.","journal-title":"Cancer Discov"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03798-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03798-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03798-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T22:02:23Z","timestamp":1781042543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03798-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":60,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2026,7,1]]}},"alternative-id":["3798"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03798-6","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"29 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests. The illustration was generated using Biorender software.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics approval for this study was obtained from the Ethics Committee of Zhujiang Hospital of Southern Medical University (2024-KY-129-01). Informed consent was obtained from all participants for the collection and use of human tissues. Animal experiments were approved by the Animal Care and Use Committee of Southern Medical University (LAEC-2022-186FS; LAEC-2024-258) and conducted in accordance with the guidelines for the care and use of laboratory animals. All studies and methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"All the authors have consented to the publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}